First patient enrolled in the phase 3 clinical trial

for systemic stem cell therapy at EB House Austria

The biopharmaceutical company Rheacell started its multicentre, worldwide phase 3 trial for the clinical testing of a stem cell therapy at the beginning of 2023. The first patient worldwide could be enrolled at the EB House Austria in Salzburg. The Austrian study center is thus setting an essential milestone for testing this innovative therapy approach. The therapy is based on so-called ABCB5+ mesenchymal stromal cells. Mainly due to the systemic effect via blood circulation, data from the first clinical trials indicate that EB wound healing is promoted internally and externally.

More information about the therapeutic agent and the study: RHEACELL >< EB-Trial